~ Buy the PREZCOBIX (cobicistat; darunavir) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR PREZCOBIX

All Clinical Trials for PREZCOBIX

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02499978 ↗	Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity	Withdrawn	Janssen Scientific Affairs, LLC	Phase 2/Phase 3	2016-05-01	This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
NCT02499978 ↗	Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity	Withdrawn	University of Colorado, Denver	Phase 2/Phase 3	2016-05-01	This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
NCT02499978 ↗	Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity	Withdrawn	Stanford University	Phase 2/Phase 3	2016-05-01	This is a clinical research study to see if switching to Darunavir/Cobicistat ((PREZCOBIX™, DRV/COBI ) and Dolutegrivir (Tivicay®, DTG) in HIV-infected individuals with undetectable HIV viral load on nucleos(t)ide reverse transcriptase inhibitor (NRTI)-containing therapy will be effective in maintaining virologic suppression at 48 weeks of treatment.
NCT02603107 ↗	Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppres	Completed	Gilead Sciences	Phase 3	2015-11-20	The primary objective of this study is to evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of boosted atazanavir (ATV) or darunavir (DRV) plus either emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC) in HIV-1 infected adults who are virologically suppressed.

Clinical Trial Conditions for PREZCOBIX

Condition Name

Condition Name for PREZCOBIX
Intervention	Trials
Healthy Subjects	1
HIV-1 Infection	1
HIV/AIDS	1
Healthy	1

Condition MeSH

Condition MeSH for PREZCOBIX
Intervention	Trials
HIV Infections	1
Acquired Immunodeficiency Syndrome	1

Clinical Trial Locations for PREZCOBIX

Trials by Country

Trials by Country for PREZCOBIX
Location	Trials
United States	26
Australia	3
Canada	3
Germany	2
Italy	2

Trials by US State

Trials by US State for PREZCOBIX
Location	Trials
Colorado	2
California	2
Connecticut	1
Washington	1
Virginia	1

Clinical Trial Progress for PREZCOBIX

Clinical Trial Phase

Clinical Trial Phase for PREZCOBIX
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	1
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for PREZCOBIX
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1

Clinical Trial Sponsors for PREZCOBIX

Sponsor Name

Sponsor Name for PREZCOBIX
Sponsor	Trials
University of Colorado, Denver	1
Stanford University	1
Gilead Sciences	1

Sponsor Type

Sponsor Type for PREZCOBIX
Sponsor	Trials
Industry	5
Other	2